Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement-Reference-Cited by-同舟云学术

Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement

Published:2022-09-22 Issue:11 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Mastorino Luca¹,Cariti Caterina¹,Susca Sara¹,Sciamarrelli Nadia¹,Borriello Silvia¹,Ortoncelli Michela¹,Stroppiana Elena¹,Verrone Anna¹,Dapavo Paolo¹,Quaglino Pietro¹,Ribero Simone¹^ORCID

Affiliation:

1. Department of Medical Sciences, Section of Dermatology University of Turin Turin Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15818

Reference8 articles.

1. Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

2. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

3. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023;Frontiers in Pharmacology;2024-07-10

2. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials;Clinical, Cosmetic and Investigational Dermatology;2024-04

3. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group;Journal of the European Academy of Dermatology and Venereology;2023-09

4. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients;Pharmaceuticals;2023-03-31

5. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study;Clinical, Cosmetic and Investigational Dermatology;2023-02